loading...

COA Instruments Distributed by Mapi Research Trust

default distrib

DPM / Diabetes Productivity Measure Diabetes Productivity Measure

Novo Nordisk (Denmark) et al.

To assess productivity impairment in patients with diabetes mellitus

Therapeutic indications : Diabetes Mellitus

default distrib

DSAS-1 / Type 1 Diabetes Stigma Assessment Scale Type 1 Diabetes Stigma Assessment Scale

Browne J, Mosely K, Ventura AD, Speight J et al.

To measure perceived and experienced stigma related to living with type 1 diabetes

Therapeutic indications : Diabetes Mellitus, Type 1

default distrib

DSAS-2 / Type 2 Diabetes Stigma Assessment Scale Type 2 Diabetes Stigma Assessment Scale

Browne J, Ventura AD, Speight J, Mosely K et al.

To measure perceived and experienced stigma related to living with type 2 diabetes

Therapeutic indications : Diabetes Mellitus, Type 2

default distrib

DSDS / Diabetes Semantic Differential Scales Diabetes Semantic Differential Scales

Fitzgerald JT, Wray LA, Shay BR, Gruppen LD, Anderson RM et al.

To measure patient and health professional/provider perceptions of 18 diabetes-related concepts

Therapeutic indications : Diabetes Mellitus

default distrib

DSM / Diabetes Symptom Measure Diabetes Symptom Measure

Novo Nordisk (Denmark) et al.

To assess symptom experience of patients with diabetes mellitus

Therapeutic indications : Diabetes Mellitus

default distrib

DSMQ / Diabetes Self-Management Questionnaire Diabetes Self-Management Questionnaire

Schmitt A et al.

To assess diabetes self-care activities associated with glycaemic control

Therapeutic indications : Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

default distrib

DSMQ-R / Diabetes Self-Management Questionnaire - Revised Diabetes Self-Management Questionnaire - Revised

Schmitt A et al.

To assess diabetes self-care activities associated with glycaemic control

Therapeutic indications : Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

default distrib

EASI / Eczema Area and Severity Index Eczema Area and Severity Index

Hanifin JM, Thurston M, Omoto M, Cherill R., Tofte SJ, Graeber M, EASI Evaluator Group et al.

To assess the extent and severity of atopic dermatitis (AD) or eczema at 4 body sites (Head/neck, Trunk, Upper extremities and Lower extremities) and measure 4 clinical signs, Erythema, Inuration/Papulation, Excoriation and Lichenification, in a simple, effective, comprehensive, consistent, and flexible way for a range of patients

Therapeutic indications : Eczema, Dermatitis, Atopic

default distrib

EPDD / Endometriosis Pain Daily Diary Endometriosis Pain Daily Diary

Astellas Pharma Europe Ltd et al.

To assess endometriosis-related pain and its impact on patients’ lives.

Therapeutic indications : Endometriosis

default distrib

ESDS / Enforced Social Dependency scale Enforced Social Dependency scale

Benoliel JQ, Young K, McCorkle R et al.

To assess levels of social dependence, regarding self-care, mobility and social competencies, and their change over time during the course of illness or under treatment

Therapeutic indications : Chronic Diseases, Neoplastic Processes

default distrib

ESS / Epworth Sleepiness Scale Epworth Sleepiness Scale

Johns MW et al.

To measure a subject's usual level of daytime sleepiness or average sleep propensity

Therapeutic indications : Sleepiness

default distrib

ESS-CHAD / Epworth Sleepiness Scale - Child Adolescent Epworth Sleepiness Scale - Child Adolescent

Johns MW et al.

To measure the subject’s average level of daytime sleepiness in daily life

Therapeutic indications : Sleepiness

default distrib

ETDQ-7 / Eustachian Tube Dysfunction Questionnaire Eustachian Tube Dysfunction Questionnaire

McCoul ED, Anand VK, Christos PJ et al.

To clinically assess symptoms and treatment outcome in Eustachian tube dysfunction (ETD)

Therapeutic indications : Eustachian tube dysfunction

default distrib

FBA / Food Benefits Assessment Food Benefits Assessment

Danone (France), Mapi et al.

To assess the perceived outcomes associated with diet/food intake in the general adult population

Therapeutic indications : All

default distrib

FBDSI / Functional Bowel Disorder Severity Index Functional Bowel Disorder Severity Index

Drossman DA, Li Z, Toner BB, Diamant NE, Creed FH, Thompson DR, Read NW, Babbs C, Barreiro M, Bank L, Whitehead WE, Schuster MM, Guthrie EA et al.

To quantify illness severity in patients with painful functional bowel disorders

Therapeutic indications : Gastrointestinal Diseases

default distrib

FDDQL / Quality of Life Questionnaire for Functional Digestive Disorders Quality of Life Questionnaire for Functional Digestive Disorders

Mapi, Chassany O, Parke D et al.

To measure the specific physical, psychological, and perpetual impacts of dyspepsia and irritable bowel syndrome

Therapeutic indications : Dyspepsia, Irritable Bowel Syndrome

default distrib

FIQ / Fibromyalgia Impact Questionnaire Fibromyalgia Impact Questionnaire

Bennett R, Burckhardt C, Clark S et al.

To measure fibromyalgia patient status, progress and outcomes

Therapeutic indications : Fibromyalgia

default distrib

FIQR / Revised Fibromyalgia Impact Questionnaire Revised Fibromyalgia Impact Questionnaire

Bennett R, Friend R et al.

To measure fibromyalgia patient status, progress and outcomes

Therapeutic indications : Fibromyalgia

default distrib

FiRST / Fibromyalgia Rapid Screening Tool Fibromyalgia Rapid Screening Tool

Perrot S, Bouhassira D et al.

Screening tool developed for the detection of fibromyalgia syndrome in patients with diffuse chronic pain

Therapeutic indications : Fibromyalgia

default distrib

FIS / Fatigue Impact Scale Fatigue Impact Scale

Fisk JD et al.

To assess the problems in patients’ quality of life that they attribute to their symptoms of fatigue

Therapeutic indications : Fatigue